USPTO Examiner PURDY KYLE A - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18897019Pathogenic Affinity Pathway of Infectious or Parasitic Organisms for Nanogram and Picogram Dosimetry Prophylaxis or CureSeptember 2024December 2024Allow300YesNo
18894811THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDERSeptember 2024March 2025Allow610NoNo
18739339PUERARIA LOBATA NANO-SILVER COMPOSITE HYDROSOL, PREPARATION METHOD AND APPLICATION THEREOFJune 2024November 2024Allow510NoNo
18413304Diphenyl Tablets and Methods of Preparing the SameJanuary 2024March 2025Abandon1410NoNo
18541832INTRAOPERATIVE TOPICALLY-APPLIED NON-IMPLANTABLE RAPID RELEASE PATCHDecember 2023February 2025Allow1420YesNo
18524738LIQUISOFT CAPSULESNovember 2023January 2025Allow1410YesNo
18384042PREPARATION METHOD FOR MODIFIED NANO-ZINC OXIDE POWDEROctober 2023April 2024Allow510NoNo
18483463COMPOSITIONS, SYSTEMS, AND METHODS FOR INCREASED PLANT QUALITYOctober 2023May 2025Allow1921YesNo
18242083ENHANCED CURCUMA LONGA PRODUCTIVITY AND MEDICINAL VALUES BY USING MORINGA OLEIFERA LEAF EXTRACTSeptember 2023January 2024Allow410NoNo
18232120PHOTOSTABLE COMPOSITIONS COMPRISING PARA-ALKOXYL PHENYL SUBSTITUTED PROPENOIC ACID (APP) COPOLYMER DERIVATIVESAugust 2023July 2024Allow1210NoNo
18356932N-Oxide and Ectoine Monomers, Polymers, Their Compositions, and Related MethodsJuly 2023December 2024Abandon1710NoNo
18211252NANOCOMPOSITE INCLUDING WATER-SOLUBLE NANO-POLYMER AND MESOPOROUS SILICA NANOPARTICLES ENCAPSULATED WITH AZOLE DERIVATIVESJune 2023August 2023Allow200NoNo
18334017COMPOSITIONS FOR CONTROLLING ARTHROPODSJune 2023September 2024Abandon1521NoNo
18334055COMPOSITIONS FOR CONTROLLING ARTHROPODSJune 2023September 2024Abandon1521NoNo
18194011ANTIVIRAL ARTICLESMarch 2023August 2024Abandon1610NoNo
18189298LIQUID CONCENTRATE FOR PRESERVATIONMarch 2023January 2025Allow2230YesYes
18174090STOVE WITH MOSQUITO REPELLENT COMPONENTFebruary 2023September 2023Allow710NoNo
18107243Solid Pharmaceutical Compositions for Treating HCVFebruary 2023September 2024Abandon1910NoNo
18100225Antibacterial Composition and its Use in Treating Bacterial InfectionsJanuary 2023May 2024Allow1620YesNo
18017027NITINOL NANOFIBERSJanuary 2023November 2023Allow911YesNo
18153696STRESS MANAGEMENT IN LIVESTOCKJanuary 2023February 2025Abandon2530NoNo
18079931COMPOSITION FOR OBTAINING A NATURAL BIOACTIVE FOR ONCOLOGIC THERAPIESDecember 2022April 2025Allow2800YesNo
17980684BIOMIMETIC NANOFIBER TISSUE SCAFFOLDSNovember 2022January 2024Abandon1410NoNo
17969266PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOFOctober 2022February 2024Allow1530NoNo
17995905FACE MASK, COMPOSITES, IRON-IRON OXIDE COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOFOctober 2022March 2025Allow2900YesNo
17935773ANTIMICROBIAL MEDICAL BIOMATERIAL AND A METHOD OF PREPARING THE SAMESeptember 2022August 2023Allow1110NoNo
17944839LUBRICATING MEMBER COMPRISING POLYGLUTAMIC ACIDSeptember 2022September 2023Abandon1210YesNo
17817919Oxime Cross-Linked Biocompatible Polymer Hydrogels and Methods of Use ThereofAugust 2022July 2024Abandon2320NoNo
17797249CONTROLLED-RELEASE FORMULATION FOR HEARING LOSS AND PREPARATION METHOD THEREFORAugust 2022May 2025Allow3401YesNo
17879259Microparticle Enabled Delivery Structures, Methods of Preparing and Using SameAugust 2022June 2025Abandon3530NoNo
17842376HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOFJune 2022October 2023Allow1610NoNo
17837103MICRONUTRIENT FORMULATIONS THAT CONTROL PLANT PATHOGENSJune 2022March 2024Abandon2111NoNo
17663296SURFACES AND COATING COMPOSITIONS HAVING ANTIFOULING, ANTITHROMBOTIC, AND ANTIBACTERIAL PROPERTIES AND METHODS OF MAKINGMay 2022January 2025Allow3211YesNo
17741358COMPOSITION AND METHOD FOR CONTROLLED DRUG RELEASE FROM A TISSUEMay 2022April 2025Abandon3540NoNo
17727213REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIESApril 2022June 2023Abandon1321NoNo
17768532USE OF A FLAVANOID EXTRACT OBTAINED FROM THE SPECIES TALIPARITI ELATUM SW, FORMULATIONS COMPRISING SAME AND TREATMENT METHODApril 2022May 2025Abandon3701NoNo
17704306LIQUISOFT CAPSULESMarch 2022August 2023Allow1710NoNo
17642769BIOLOGICAL TISSUE ADHESIVE SHEET, BIOLOGICAL TISSUE REINFORCEMENT MATERIAL KIT, AND METHOD FOR PRODUCING BIOLOGICAL TISSUE ADHESIVE SHEETMarch 2022November 2024Abandon3230NoNo
17687939STAMINA-IMPROVING COMPOSITION AND STAMINA-IMPROVING NATURAL TEA COMPRISING SAMEMarch 2022March 2025Allow3610YesNo
17803133Topical Skin TreatmentFebruary 2022June 2023Allow1500YesNo
17677419LIGHT-ACTIVATED CHLORINE DIOXIDE-RELEASING POWDER AND METHOD OF MANUFACTUREFebruary 2022February 2024Allow2421YesYes
17671594ANTIBACTERIAL AND ANTIFUNGAL POLYESTER MATERIALFebruary 2022March 2024Allow2520YesNo
17585504FORMULATIONS FOR CORNEAL APPLICATIONJanuary 2022February 2024Abandon2541YesYes
17605483COMPOSITION COMPRISING ACTINIDIA POLYGAMA EXTRACT FOR ALLEVIATING SKIN DAMAGE OR MOISTURIZING SKINJanuary 2022February 2025Abandon4010NoNo
17628449METHOD FOR EXTRACTIONJanuary 2022April 2025Abandon3901NoNo
17597488ARTICLES CONTAINING A CROSSLINKED GUANIDINYL-CONTAINING POLYMER AND USES THEREOFJanuary 2022January 2025Allow3620YesYes
17624851MEDICINE FOR TREATING PULMONARY MYCOSISJanuary 2022April 2025Abandon3910NoNo
17567892TryNOVID Boosts Immune System Against Viruses and VariantsJanuary 2022August 2024Allow3100YesNo
17567599COMPOSITIONS AND ARTICLES COMPRISING COMPLEXES OF 1-METHYLCYCLOPROPENE AND ALPHA-CYCLODEXTRINJanuary 2022February 2024Allow2520YesNo
17646655HYDROXIDES MONOLAYER NANOPLATELET AND METHODS OF PREPARING SAMEDecember 2021November 2024Abandon3421YesNo
17622541PHARMACEUTICAL COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH, COMPRISING GINSENOSIDE RG4 OR MIXTURE (RGX 365) OF GINSENOSIDES RG2, RG4, RG6, AND RH1 AS ACTIVE INGREDIENTDecember 2021June 2025Allow4111NoNo
17644745COLLOIDAL PARTICLE FORMULATIONS WITH ADVANCED FUNCTIONALITYDecember 2021August 2023Allow2021YesNo
17618013PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASESDecember 2021January 2025Abandon3710NoNo
17551719INSECT CONTROL PRODUCT FOR ANIMALSDecember 2021September 2024Abandon3320NoNo
17548976Use Of A Composition For The Pigmentation Of Hair And HairsDecember 2021May 2025Abandon4110NoNo
17617009AN ANTIMICROBIAL COATING COMPOSITIONDecember 2021February 2025Abandon3901NoNo
17534667METHOD OF TREATING OR AMELIORATING SKIN CONDITIONS WITH A MAGNETIC DIPOLE STABILIZED SOLUTIONNovember 2021August 2023Abandon2110NoNo
17453101METHODS AND COMPOSITIONS FOR TREATING HYPERHIDROSISNovember 2021June 2023Allow1910NoNo
17506967PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT FROM CAMELLIA JAPONICA AS ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONOctober 2021December 2024Abandon3810NoNo
17417992COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING BRIDALWREATH SPIREAOctober 2021May 2025Abandon4620NoNo
17600910VARIOUS USES OF THE NANOPARTICULATE COMPOUND OF TITANIUM DIOXIDE FUNCTIONALIZEDOctober 2021April 2024Abandon3020NoNo
17600793SYNERGISTIC HERBAL COMPOSITIONS FOR PREVENTION, TREATMENT OR CONTROL OF PAIN AND/OR CARTILAGE REGENERATIONOctober 2021June 2025Abandon4521YesNo
17599844AGENT FOR CONTROLLING PESTS SUCH AS RODENTSSeptember 2021November 2024Abandon3810NoNo
17442483METHODS FOR CONTINUOUS EXTRACTION AND PURIFICATION OF A UNIQUE FLAVAN-3-OL EXTRACT FROM IMMATURE WHOLE GRAPE CLUSTERS AND COMPOSITIONS THEREOFSeptember 2021November 2024Abandon3801NoNo
17593444FREEZE-DRIED FORMULATION, PREPARATION METHOD AND APPLICATION THEREOFSeptember 2021June 2025Abandon4521NoNo
17439169AQUEOUS AGROCHEMICAL SUSPENSION COMPOSITION AND METHOD FOR SPRAYING SAMESeptember 2021December 2022Allow1520YesNo
17462316BIOMIMETIC NANOFIBER TISSUE SCAFFOLDSAugust 2021August 2022Allow1211NoNo
17461667BIOMIMETIC NANOFIBER TISSUE SCAFFOLDSAugust 2021August 2022Allow1211NoNo
17433805MAQUI BERRY EXTRACTS FOR USE IN THE TREATMENT OR PREVENTION OF BONE DISORDERSAugust 2021March 2025Abandon4310NoNo
17403097ANTIVIRAL METAL TREATMENTS FOR FIBER SUBSTRATES, FILTER MEDIA HAVING ANTIVIRAL METAL TREATMENTS, AND PROCESSES FOR TREATING FIBER SUBSTRATESAugust 2021October 2024Abandon3840YesNo
17392833Antiviral Antimicrobial ArticleAugust 2021January 2024Abandon2931YesYes
17384480Photostable Compositions Comprising Para-Alkoxyl Phenyl Substituted Propenoic Acid (APP) Copolymer DerivativesJuly 2021May 2023Allow2110NoNo
17364968SKIN CARE FORMULATIONJuly 2021May 2023Abandon2210NoNo
17365055COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF LOWER URINARY TRACT SYMPTOMSJuly 2021June 2024Allow3510NoNo
17304890SPATIOTEMPORAL DELIVERY SYSTEM EMBEDDED IN 3D-PRINTINGJune 2021May 2024Abandon3420NoNo
17304689COLOR INK SET FOR COSMETIC APPLICATIONJune 2021August 2023Abandon2620YesNo
17415368METHOD FOR PREPARING A BIOCIDAL, BACTERIOCIDAL AND/OR BACTERIOSTATIC MATERIALJune 2021October 2024Allow4011YesNo
17348026PESTICIDE-CONTAINING SOIL DISINFESTATION MATERIAL WITHOUT USE OF FUMIGANTJune 2021February 2024Allow3240NoNo
17413714CERIUM OXIDE NANOPARTICLE, DECOMPOSITION METHOD OF NUCLEIC ACID, DECOMPOSITION METHOD OF POLYPEPTIDE, METHOD OF PRODUCING CERIUM OXIDE NANOPARTICLE, OXIDIZING AGENT, ANTIOXIDANT, ANTIFUNGAL AGENT, AND ANTI-VIRUS AGENTJune 2021December 2023Allow3030YesNo
17347267ANTIMICROBIAL ARTICLE AND MANUFACTURING METHOD THEREOFJune 2021July 2023Abandon2511NoNo
17326948ANTIMICROBIAL/ANTIVIRAL NONWOVEN AND APPLICATIONS OF THE SAMEMay 2021July 2023Abandon2620NoNo
17295679COMPOSITION FOR USE IN THE PREVENTION AND/OR SYMPTOMATIC TREATMENT OF IRRITABLE BOWEL SYNDROMEMay 2021September 2024Abandon4010NoNo
17317937ANTIBACTERIAL COATING MATERIAL, METHOD OF MANUFACTURING AN ANTIBACTERIAL COATING MATERIAL, ANTIBACTERIAL COATING LAYER AND ANTIVIRAL ADHESIVE TAPEMay 2021February 2023Abandon2101NoNo
17244908BIOMIMETIC NANOFIBER TISSUE SCAFFOLDSApril 2021August 2021Allow301YesNo
17243524SYSTEM AND METHOD FOR IMPREGNATING A POROUS SURFACE WITH ANTIBACTERIAL AND ANTIVIRAL COMPOUNDSApril 2021August 2024Allow4031YesNo
17235827COATING FOR CAPTURING AND KILLING VIRUSES ON SURFACESApril 2021September 2022Allow1601YesNo
17286611WITHANIA SOMNIFERA COMPOSITION, METHOD OF PREPARATION AND USE THEREOFApril 2021July 2024Allow3910YesNo
17232808POLYMERIC MICELLES CONTAINING AN ESSENTIAL OIL COMPOUND AND A METHOD OF MAKING SAMEApril 2021September 2024Abandon4131YesNo
17228251ANTIBIOTIC-FREE ANTIMICROBIAL FEED ADDITIVES AND ANTIMICROBIAL COMPOSITIONSApril 2021June 2024Abandon3941NoNo
17227326ANTIVIRAL FIBERS, FABRICS AND FABRIC-BASED PRODUCTSApril 2021June 2023Abandon2720NoNo
17280975PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES, CONTAINING ANGELICA GIGAS NAKAI EXTRACT OR MIXED EXTRACT OF ANGELICA GIGAS NAKAI AND BROCCOLIMarch 2021January 2025Allow4611YesNo
17213521COUGH PATCH WITH GERMICIDAL AND/OR ANTIMICROBIAL PROPERTIESMarch 2021February 2023Abandon2310NoNo
17206496COPPER MICROBE STOPPERMarch 2021December 2024Allow4541YesNo
17275264COMPOSITIONS COMPRISING CBD FOR TREATING DERMATOLOGICAL CONDITIONSMarch 2021July 2024Abandon4010NoNo
17192533ANTIVIRAL ARTICLESMarch 2021December 2022Allow2220NoNo
17269231TISSUE ENGINEERING BONE SCAFFOLD AND PREPARATION METHOD THEREOFFebruary 2021September 2022Abandon1910NoNo
17170013ANTIMICROBIAL MEDICAL BIOMATERIAL AND A METHOD FOR PREPARING THE SAMEFebruary 2021April 2023Allow2611NoNo
17260850COMPLEX OXIDE CERAMIC, METHOD FOR PRODUCING SAME, AND ARTICLEJanuary 2021September 2023Allow3220NoNo
17247808COLLOIDAL PARTICLE FORMULATIONS WITH ADVANCED FUNCTIONALITYDecember 2020March 2025Allow5081YesNo
17255770SUBSTITUTED 2-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTSDecember 2020July 2023Allow3100NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PURDY, KYLE A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
53
Examiner Affirmed
41
(77.4%)
Examiner Reversed
12
(22.6%)
Reversal Percentile
35.0%
Lower than average

What This Means

With a 22.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
220
Allowed After Appeal Filing
39
(17.7%)
Not Allowed After Appeal Filing
181
(82.3%)
Filing Benefit Percentile
18.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PURDY, KYLE A - Prosecution Strategy Guide

Executive Summary

Examiner PURDY, KYLE A works in Art Unit 1611 and has examined 963 patent applications in our dataset. With an allowance rate of 41.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner PURDY, KYLE A's allowance rate of 41.6% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PURDY, KYLE A receive 2.87 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PURDY, KYLE A is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +39.9% benefit to allowance rate for applications examined by PURDY, KYLE A. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 10.0% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 23.5% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 57.3% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 38.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.1% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.0% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.0% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.